מכפיל P/S עתידי: IceCure Medical Ltd. (ICCM)

Sales of advanced ProSense systems are driving the current growth of IceCure Medical Ltd (ICCM). The application of minimally invasive cryoablation methods reduces waste, supporting the principles of sustainable healthcare. The forward P/S history demonstrates valuation dynamics, where the value has stabilized at 0.60. However, risks are associated with slow technology adoption by physicians, dependence on insurance reimbursements, and the need for FDA approval.

To protect portfolio capital, priority is given to assets with predictable revenue growth, which for IceCure Medical Ltd (ICCM) is driven by high operating leverage from the sale of disposable cryoprobes. The trend of the future P/S metric reflects the market valuation of expected sales volume relative to market capitalization, allowing investors to determine the extent of future income compression under the influence of inflationary pressure and operating expenses.